Arcutis Biotherapeutics (ARQT) Competitors $14.29 -0.29 (-1.99%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$14.39 +0.10 (+0.67%) As of 08/1/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARQT vs. GRFS, TGTX, NUVL, RYTM, CRSP, AXSM, TLX, LNTH, PCVX, and MTSRShould you be buying Arcutis Biotherapeutics stock or one of its competitors? The main competitors of Arcutis Biotherapeutics include Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Rhythm Pharmaceuticals (RYTM), CRISPR Therapeutics (CRSP), Axsome Therapeutics (AXSM), Telix Pharmaceuticals (TLX), Lantheus (LNTH), Vaxcyte (PCVX), and Metsera (MTSR). These companies are all part of the "pharmaceutical products" industry. Arcutis Biotherapeutics vs. Its Competitors Grifols TG Therapeutics Nuvalent Rhythm Pharmaceuticals CRISPR Therapeutics Axsome Therapeutics Telix Pharmaceuticals Lantheus Vaxcyte Metsera Grifols (NASDAQ:GRFS) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings. Which has preferable valuation and earnings, GRFS or ARQT? Grifols has higher revenue and earnings than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrifols$7.81B0.95$169.80M$1.179.21Arcutis Biotherapeutics$196.54M8.67-$140.04M-$1.04-13.74 Is GRFS or ARQT more profitable? Grifols has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -60.95%. Grifols' return on equity of 0.00% beat Arcutis Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets GrifolsN/A N/A N/A Arcutis Biotherapeutics -60.95%-80.66%-32.94% Do analysts prefer GRFS or ARQT? Grifols presently has a consensus target price of $10.30, indicating a potential downside of 4.45%. Arcutis Biotherapeutics has a consensus target price of $19.40, indicating a potential upside of 35.76%. Given Arcutis Biotherapeutics' higher possible upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grifols 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00Arcutis Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Which has more risk and volatility, GRFS or ARQT? Grifols has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.84, meaning that its stock price is 84% more volatile than the S&P 500. Does the media favor GRFS or ARQT? In the previous week, Grifols had 1 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 8 mentions for Grifols and 7 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.99 beat Grifols' score of 0.52 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcutis Biotherapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryGrifols beats Arcutis Biotherapeutics on 10 of the 15 factors compared between the two stocks. Get Arcutis Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARQT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARQT vs. The Competition Export to ExcelMetricArcutis BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.74B$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-13.7417.6228.6723.80Price / Sales8.67179.18373.9066.58Price / CashN/A41.9535.4557.96Price / Book10.598.508.275.55Net Income-$140.04M-$55.06M$3.24B$259.03M7 Day Performance-3.84%-3.98%-3.69%-4.59%1 Month Performance3.85%9.59%4.33%4.46%1 Year Performance54.49%6.72%25.95%18.03% Arcutis Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARQTArcutis Biotherapeutics2.5048 of 5 stars$14.29-2.0%$19.40+35.8%+50.7%$1.74B$196.54M-13.74150News CoveragePositive NewsUpcoming EarningsGRFSGrifols3.116 of 5 stars$10.00+0.6%$10.30+3.0%+41.1%$6.83B$7.81B8.5523,822Dividend AnnouncementTGTXTG Therapeutics4.0794 of 5 stars$37.42-1.3%$43.80+17.0%+85.0%$6.02B$329M157.96290Positive NewsUpcoming EarningsNUVLNuvalent3.2323 of 5 stars$82.46-1.1%$119.60+45.0%+2.0%$5.99BN/A-18.7840Positive NewsRYTMRhythm Pharmaceuticals3.4446 of 5 stars$88.63-0.6%$91.93+3.7%+88.5%$5.68B$130.13M-31.54140Upcoming EarningsInsider TradeCRSPCRISPR Therapeutics2.7909 of 5 stars$65.33+0.3%$71.75+9.8%+2.3%$5.62B$37.31M-14.45460Upcoming EarningsAnalyst RevisionGap DownHigh Trading VolumeAXSMAxsome Therapeutics4.8236 of 5 stars$109.68-1.8%$172.33+57.1%+19.8%$5.50B$385.69M-19.01380Positive NewsUpcoming EarningsTLXTelix PharmaceuticalsN/A$16.50+1.7%$22.33+35.4%N/A$5.49B$516.72M0.00N/AGap DownHigh Trading VolumeLNTHLantheus4.6193 of 5 stars$71.56+2.0%$131.20+83.3%-28.4%$4.86B$1.53B20.33700News CoverageUpcoming EarningsAnalyst RevisionPCVXVaxcyte2.2389 of 5 stars$35.64-1.6%$136.50+283.0%-58.0%$4.67BN/A-8.93160News CoveragePositive NewsUpcoming EarningsMTSRMetseraN/A$39.91-6.6%$55.00+37.8%N/A$4.49BN/A0.0081News CoverageEarnings ReportLockup ExpirationAnalyst RevisionGap Up Related Companies and Tools Related Companies GRFS Competitors TGTX Competitors NUVL Competitors RYTM Competitors CRSP Competitors AXSM Competitors TLX Competitors LNTH Competitors PCVX Competitors MTSR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARQT) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcutis Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
